India's Richest People 2026 edition · 1 director · Source: Hurun India
- #139 Harsh Vardhan Goenka & family ₹25,500 Cr
Market Cap
₹4,968 Cr
RPGLIFE · NSE
Share Price
₹2,663.40
-11.33% today
Revenue
₹708 Cr
FY 2025-26 · +8.3% YoY
EBITDA
₹127 Cr
Margin 18.0%
Net Profit
₹110 Cr
FY 2025-26 · -5.1% YoY
P/E (TTM)
40.1x
P/B 7.8x
ROE
20.3%
ROCE 26.6%
Debt / Equity
0.02
Interest cover 1.7x
About RPG Life Sciences Limited
Data last updated:
RPG Life Sciences Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 29 March 2007 and has been in existence for over 19 years.
Its director Harsh Vardhan Goenka and family are #139 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24232MH2007PLC169354. Its GSTIN is 27AADCR8060K1Z1 (Maharashtra). The company holds 19 GST registrations, of which 17 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532983 and NSE: RPGLIFE.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.23 Cr. It was formerly known as Rpg Pharmaceuticals Limited. It is led by directors including Ashok Nair (Managing Director) and Manojkumar Madangopal Maheshwari.
Its last annual general meeting (AGM) was held on 16 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹707.52 Cr, a growth of 8.3% compared to the previous year. For the same year it recorded a net profit of ₹109.67 Cr (net margin 15.5%) and EBITDA of ₹127.12 Cr (EBITDA margin 18%). The net worth stands at ₹605.35 Cr (up 14.1% YoY). Total assets are valued at ₹636.2 Cr (up 18.3% YoY).
The company has about 1,197 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: RPG Life Sciences. As per MCA filings, the company has open charges of ₹65.92 Cr and satisfied charges of ₹71.07 Cr on record. Court records list 205 cases involving the company, including 99 filed by the company and 106 filed against it; 37 cases are pending. The company has 37 deals on record (32 market trades, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹5.07 Cr; the latest was in April 2026. Its 8 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Wallace Pharmaceuticals Private Limited with revenue of ₹673.06 Cr. The company has 10 MSME Form 1 returns on record between 2020 and 2023, listing 173 overdue payments to 58 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rpglifesciences.com.
Company details
CIN L24232MH2007PLC169354
Registration Number 169354
Incorporation Date 29 March 2007
ROC Mumbai
Listing Status Listed - Listed on NSE (RPGLIFE); Listed on BSE (532983)
Company Status Active
Date of Last AGM 16 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
RPG Life Sciences has one previous CIN (Corporate Identification Number): U24232MH2007PLC169354. The current CIN is L24232MH2007PLC169354, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232MH2007PLC169354 | Current |
| U24232MH2007PLC169354 | Previous |
Key People
Ashok Nair Managing Director Manojkumar Madangopal Maheshwari Director Yugal Kishor Chothuram Sikri Director Recognitions & Rankings of RPG Life Sciences
Contact details
RPG Life Sciences Limited's registered office is in Mumbai, Maharashtra. Its website is rpglifesciences.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressRpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
- IndustryPharma, API Manufacturers, Drug Formulation & Development
To see the full contact details of RPG Life Sciences Limited, buy the company report.
Comprehensive company report
RPG Life Sciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
RPG Life Sciences operates one associated brand: RPG Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generics and APIs are manufactured by RPG Life Sciences. | rpglifesciences.com |
Business activity
The main business activity of RPG Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of RPG Life Sciences Limited, buy the company report.
Financials of RPG Life Sciences Limited
FY 2025-26 filings availableRPG Life Sciences Limited reported revenue of ₹707.52 Cr (up 8.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹708 Cr
+8.3% YoY
EBITDA
₹127 Cr
-11.9% YoY
Profit After Tax
₹110 Cr
-5.1% YoY
Net Worth
₹605 Cr
+14.1% YoY
Total Assets
₹636 Cr
+18.3% YoY
Total Debt
₹20.00 Cr
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 708 | 653 |
| Revenue growth | +8.3% | - |
| EBITDA | 127 | 144 |
| EBITDA margin | +18.0% | +22.1% |
| Profit before tax | 154 | 233 |
| Net profit | 110 | 116 |
| Net profit margin | +15.5% | +17.7% |
| EPS (₹) | 69.64 | 110.80 |
| Balance sheet | ||
| Total assets | 636 | 538 |
| Net worth | 605 | 531 |
| Total debt | 20.00 | 0.00 |
| Cash & bank | 192 | 140 |
| Net working capital | 322 | 220 |
| Cash flow | ||
| Cash from operations | 56.50 | 77.86 |
| Cash from investing | 85.84 | (41.80) |
| Cash from financing | (20.58) | (27.08) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 196 | 177 | 180 | 182 | 169 | 143 | 173 |
| Revenue growth (YoY) | +15.9% | +23.6% | +4.2% | - | - | - | - |
| Other income | 4.70 | 13.50 | 3.41 | 15.76 | 5.23 | 115 | 3.31 |
| EBITDA | 43.29 | 32.83 | 31.34 | 39.03 | 35.47 | 25.49 | 49.16 |
| EBITDA margin | +22.1% | +18.6% | +17.4% | +21.5% | +21.0% | +17.8% | +28.5% |
| Depreciation | 5.90 | 5.74 | 5.38 | 5.22 | 5.14 | 5.37 | 5.46 |
| Interest | 0.63 | 0.39 | 0.25 | 0.12 | 0.13 | 0.18 | 0.12 |
| Profit before tax | 41.46 | 40.20 | 29.12 | 49.45 | 35.43 | 135 | 46.89 |
| Tax | 10.70 | 10.30 | 6.99 | 12.60 | 9.14 | 17.55 | 11.96 |
| Net profit | 30.76 | 29.90 | 22.13 | 36.85 | 26.29 | 117 | 34.93 |
| EPS (₹) | 18.60 | 18.08 | 13.38 | 22.28 | 15.90 | 70.96 | 21.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 708 | 653 | 582 | 513 | 440 | 389 | 376 |
| Revenue growth | +8.3% | +12.3% | +13.5% | +16.5% | +13.1% | +3.6% | - |
| EBITDA | 127 | 144 | 129 | 104 | 87.25 | 70.93 | 54.84 |
| EBITDA margin | +18.0% | +22.1% | +22.2% | +20.2% | +19.8% | +18.2% | +14.6% |
| Profit before tax | 154 | 233 | 118 | 91.68 | 73.17 | 53.58 | 36.45 |
| Net profit | 110 | 116 | 86.89 | 68.21 | 50.87 | 40.01 | 32.94 |
| Net profit margin | +15.5% | +17.7% | +14.9% | +13.3% | +11.6% | +10.3% | +8.8% |
| EPS (₹) | 69.64 | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | 17.54 |
| Balance sheet | |||||||
| Total assets | 636 | 538 | 382 | 315 | 263 | 225 | 194 |
| Net worth | 605 | 531 | 375 | 308 | 256 | 216 | 177 |
| Total debt | 20.00 | 0.00 | 0.00 | 0.01 | 0.94 | 2.02 | 11.72 |
| Cash & bank | 157 | 140 | 36.47 | 57.04 | 70.26 | 40.75 | 1.11 |
| Net working capital | 287 | 220 | 76.98 | 103 | 127 | 97.44 | 53.39 |
| Cash flow | |||||||
| Cash from operations | 56.50 | 77.86 | 94.36 | 90.82 | 64.75 | 58.27 | 50.17 |
| Cash from investing | 51.06 | (41.80) | (79.15) | (106) | (34.66) | (7.96) | (10.70) |
| Cash from financing | (20.58) | (27.08) | (20.31) | (17.12) | (13.51) | (10.49) | (39.30) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 196 | 177 | 180 | 182 | 169 | 143 | 173 | 172 |
| Revenue growth (YoY) | +15.9% | +23.6% | +4.2% | +5.5% | +2.1% | - | - | - |
| Other income | 4.16 | 13.46 | 3.41 | 15.76 | 5.23 | 115 | 3.31 | 1.94 |
| Total expenses | 152 | 144 | 149 | 143 | 133 | 118 | 124 | 154 |
| EBITDA | 43.58 | 32.87 | 31.34 | 39.03 | 35.47 | 25.49 | 49.16 | 18.63 |
| EBITDA margin | +22.3% | +18.6% | +17.4% | +21.5% | +21.0% | +17.8% | +28.5% | +10.8% |
| Depreciation | 5.90 | 5.74 | 5.38 | 5.22 | 5.14 | 5.37 | 5.46 | 5.31 |
| Interest | 0.63 | 0.39 | 0.25 | 0.12 | 0.13 | 0.18 | 0.12 | 0.17 |
| Profit before tax | 41.21 | 40.20 | 29.12 | 49.45 | 35.43 | 135 | 46.89 | 15.09 |
| Tax | 10.64 | 10.30 | 6.99 | 12.60 | 9.14 | 17.55 | 11.96 | 10.89 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 196 | 177 | 180 | 182 | 169 | 143 | 173 |
| Revenue growth (YoY) | +15.9% | +23.6% | +4.2% | - | - | - | - |
| Other income | 4.70 | 13.50 | 3.41 | 15.76 | 5.23 | 115 | 3.31 |
| EBITDA | 43.29 | 32.83 | 31.34 | 39.03 | 35.47 | 25.49 | 49.16 |
| EBITDA margin | +22.1% | +18.6% | +17.4% | +21.5% | +21.0% | +17.8% | +28.5% |
| Depreciation | 5.90 | 5.74 | 5.38 | 5.22 | 5.14 | 5.37 | 5.46 |
| Interest | 0.63 | 0.39 | 0.25 | 0.12 | 0.13 | 0.18 | 0.12 |
| Profit before tax | 41.46 | 40.20 | 29.12 | 49.45 | 35.43 | 135 | 46.89 |
| Tax | 10.70 | 10.30 | 6.99 | 12.60 | 9.14 | 17.55 | 11.96 |
| Net profit | 30.76 | 29.90 | 22.13 | 36.85 | 26.29 | 117 | 34.93 |
| EPS (₹) | 18.60 | 18.08 | 13.38 | 22.28 | 15.90 | 70.96 | 21.12 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 708 | 653 |
| Revenue growth | +8.3% | - |
| Other income | 50.33 | 112 |
| Total expenses | 580 | 509 |
| Employee cost | 141 | 126 |
| EBITDA | 127 | 144 |
| EBITDA margin | +18.0% | +22.1% |
| Depreciation | 21.48 | 21.43 |
| Interest | 1.77 | 1.59 |
| Profit before tax | 154 | 233 |
| Tax | 39.03 | 49.64 |
| Net profit | 110 | 116 |
| Net profit margin | +15.5% | +17.7% |
| EPS (₹) | 69.64 | 110.80 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 13.23 | 13.23 |
| Reserves & surplus | 592 | 517 |
| Shareholders' funds (net worth) | 605 | 531 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 20.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 |
| Total debt | 20.00 | 0.00 |
| Total liabilities | 636 | 538 |
| Assets | ||
| Gross block | 321 | 276 |
| Net block | 197 | 172 |
| Capital work in progress | 23.29 | 16.06 |
| Investments | 84.91 | 127 |
| Inventories | 124 | 92.98 |
| Sundry debtors | 117 | 86.76 |
| Cash & bank balances | 192 | 140 |
| Loans & advances | 43.50 | 20.00 |
| Total current assets | 476 | 339 |
| Total current liabilities | 154 | 120 |
| Net working capital | 322 | 220 |
| Total assets | 636 | 538 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 28.70 | 19.72 |
| Net cash from operating activities | 56.50 | 77.86 |
| Net cash from investing activities | 85.84 | (41.80) |
| Net cash from financing activities | (20.58) | (27.08) |
| Net change in cash | 122 | 8.98 |
| Closing cash | 192 | 140 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +8.3% | - |
| EBITDA growth | -11.9% | - |
| PBT growth | -33.8% | +9997.0% |
| Net income growth | -5.1% | - |
| Profitability & leverage | ||
| Net income margin | +16.3% | +28.0% |
| Return on capital employed | +26.6% | +27.6% |
| Return on net worth | +20.3% | +21.8% |
| Debt / equity | 0.02 | 0.00 |
| Long-term debt / equity | 0.01 | 0.00 |
| Interest cover | 1.68 | 1.29 |
| Efficiency & per share | ||
| Fixed asset turnover | 2.37 | 2.37 |
| Inventory turnover | 6.53 | 7.03 |
| Debtors turnover | 6.96 | 7.53 |
| EPS (₹) | 69.64 | 110.80 |
| Dividend per share (₹) | 24.00 | 24.00 |
| Book value per share (₹) | 366.05 | 320.80 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 196 | 177 | 180 | 182 | 169 | 143 | 173 | 172 |
| Revenue growth (YoY) | +15.9% | +23.6% | +4.2% | +5.5% | +2.1% | - | - | - |
| Other income | 4.16 | 13.46 | 3.41 | 15.76 | 5.23 | 115 | 3.31 | 1.94 |
| Total expenses | 152 | 144 | 149 | 143 | 133 | 118 | 124 | 154 |
| EBITDA | 43.58 | 32.87 | 31.34 | 39.03 | 35.47 | 25.49 | 49.16 | 18.63 |
| EBITDA margin | +22.3% | +18.6% | +17.4% | +21.5% | +21.0% | +17.8% | +28.5% | +10.8% |
| Depreciation | 5.90 | 5.74 | 5.38 | 5.22 | 5.14 | 5.37 | 5.46 | 5.31 |
| Interest | 0.63 | 0.39 | 0.25 | 0.12 | 0.13 | 0.18 | 0.12 | 0.17 |
| Profit before tax | 41.21 | 40.20 | 29.12 | 49.45 | 35.43 | 135 | 46.89 | 15.09 |
| Tax | 10.64 | 10.30 | 6.99 | 12.60 | 9.14 | 17.55 | 11.96 | 10.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 708 | 653 | 582 | 513 | 440 | 389 | 376 |
| Revenue growth | +8.3% | +12.3% | +13.5% | +16.5% | +13.1% | +3.6% | - |
| Other income | 50.29 | 112 | 7.21 | 4.80 | 2.99 | 0.91 | 0.73 |
| Total expenses | 580 | 509 | 453 | 409 | 353 | 318 | 321 |
| Employee cost | 141 | 126 | 132 | 117 | 99.97 | 94.66 | 90.97 |
| EBITDA | 127 | 144 | 129 | 104 | 87.25 | 70.93 | 54.84 |
| EBITDA margin | +18.0% | +22.1% | +22.2% | +20.2% | +19.8% | +18.2% | +14.6% |
| Depreciation | 21.48 | 21.43 | 17.07 | 15.50 | 15.66 | 16.47 | 16.36 |
| Interest | 1.77 | 1.59 | 1.44 | 1.15 | 1.41 | 1.79 | 2.76 |
| Profit before tax | 154 | 233 | 118 | 91.68 | 73.17 | 53.58 | 36.45 |
| Tax | 39.03 | 49.64 | 30.18 | 24.04 | 21.69 | 13.58 | 7.44 |
| Net profit | 110 | 116 | 86.89 | 68.21 | 50.87 | 40.01 | 32.94 |
| Net profit margin | +15.5% | +17.7% | +14.9% | +13.3% | +11.6% | +10.3% | +8.8% |
| EPS (₹) | 69.64 | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | 17.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 13.23 | 13.23 | 13.23 | 13.23 | 13.23 | 13.23 | 13.23 |
| Reserves & surplus | 592 | 517 | 362 | 294 | 243 | 203 | 163 |
| Shareholders' funds (net worth) | 605 | 531 | 375 | 308 | 256 | 216 | 177 |
| Secured loans | 20.00 | 0.00 | 0.00 | 0.01 | 0.22 | 0.26 | 6.52 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.72 | 1.76 | 5.20 |
| Total debt | 20.00 | 0.00 | 0.00 | 0.01 | 0.94 | 2.02 | 11.72 |
| Total liabilities | 636 | 538 | 382 | 315 | 263 | 225 | 194 |
| Assets | |||||||
| Gross block | 321 | 276 | 222 | 220 | 186 | 180 | 174 |
| Net block | 197 | 172 | 114 | 124 | 104 | 113 | 123 |
| Capital work in progress | 23.29 | 16.06 | 96.31 | 25.44 | 31.06 | 11.77 | 9.98 |
| Investments | 120 | 127 | 91.16 | 58.43 | 0.00 | 0.00 | 0.00 |
| Inventories | 124 | 92.98 | 101 | 95.05 | 82.99 | 58.33 | 46.61 |
| Sundry debtors | 117 | 86.76 | 49.13 | 37.43 | 32.99 | 57.42 | 63.33 |
| Cash & bank balances | 157 | 140 | 36.47 | 57.04 | 70.26 | 40.75 | 1.11 |
| Loans & advances | 43.49 | 20.00 | 21.34 | 16.10 | 20.67 | 19.35 | 14.73 |
| Total current assets | 441 | 339 | 208 | 206 | 207 | 176 | 126 |
| Total current liabilities | 154 | 120 | 131 | 103 | 79.47 | 78.41 | 72.39 |
| Net working capital | 287 | 220 | 76.98 | 103 | 127 | 97.44 | 53.39 |
| Total assets | 636 | 538 | 382 | 315 | 263 | 225 | 194 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 28.70 | 19.72 | 24.82 | 56.94 | 40.36 | 0.54 | 0.37 |
| Net cash from operating activities | 56.50 | 77.86 | 94.36 | 90.82 | 64.75 | 58.27 | 50.17 |
| Net cash from investing activities | 51.06 | (41.80) | (79.15) | (106) | (34.66) | (7.96) | (10.70) |
| Net cash from financing activities | (20.58) | (27.08) | (20.31) | (17.12) | (13.51) | (10.49) | (39.30) |
| Net change in cash | 86.98 | 8.98 | (5.10) | (32.11) | 16.58 | 39.82 | 0.17 |
| Closing cash | 157 | 140 | 36.47 | 57.04 | 70.26 | 40.75 | 1.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.3% | +12.3% | +13.5% | +16.5% | +13.1% | +3.6% | - |
| EBITDA growth | -11.9% | +11.7% | +24.7% | +18.7% | +23.0% | +29.3% | - |
| PBT growth | -33.8% | +97.6% | +28.5% | +25.3% | +36.6% | +47.0% | +142.2% |
| Net income growth | -5.1% | +33.0% | +27.4% | +34.1% | +27.1% | +21.5% | - |
| Revenue CAGR (3Y) | +11.3% | +14.1% | +14.4% | +10.9% | +10.1% | +4.2% | +8.6% |
| EBITDA CAGR (3Y) | +7.1% | +18.3% | +22.1% | +23.6% | +36.3% | +22.7% | +23.8% |
| Profitability & leverage | |||||||
| Net income margin | +16.3% | +28.0% | +15.1% | +13.2% | +11.7% | +10.3% | +7.7% |
| Return on capital employed | +26.6% | +32.3% | +34.3% | +32.2% | +30.6% | +26.4% | +22.5% |
| Return on net worth | +20.3% | +25.5% | +25.7% | +24.0% | +21.8% | +20.4% | +19.5% |
| Debt / equity | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.14 |
| Long-term debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Interest cover | 1.67 | 1.29 | 1.28 | 1.31 | 1.97 | 3.29 | 7.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.37 | 2.63 | 2.64 | 2.52 | 2.40 | 2.20 | 2.23 |
| Inventory turnover | 6.53 | 6.74 | 5.94 | 5.76 | 6.23 | 7.42 | 8.57 |
| Debtors turnover | 6.96 | 9.62 | 13.45 | 14.56 | 9.74 | 6.45 | 7.35 |
| EPS (₹) | 69.64 | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | 17.54 |
| Dividend per share (₹) | 24.00 | 24.00 | 16.00 | 12.00 | 9.60 | 7.20 | 4.00 |
| Book value per share (₹) | 366.06 | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 | 106.77 |
To see the full year-wise statements and ratios of RPG Life Sciences Limited, buy the company report.
Board of directors of RPG Life Sciences Limited
RPG Life Sciences has 13 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manojkumar Madangopal Maheshwari Also directs: Algo Vantage LLP, Maheshwari Investors Private Limited, R J Investment Private Limited and 1 more | Director | 06 Feb 2008 | 18 Years 8 Months | Current |
| Yugal Kishor Chothuram Sikri Also directs: Synokem Pharmaceuticals Limited, Aic-Nmims Incubation Centre | Director | 01 May 2025 | 1 Years 5 Months | Current |
| Harsh Vardhan Goenka Also directs: Sri Parvathi Suthan Trading Company LLP, Allwin Apartments LLP, Swallow Associates LLP and 5 more | Director | 06 Feb 2008 | 18 Years 8 Months | Current |
| Rajat Bhargava Also directs: Spencer International Hotels Limited, Raychem-Rpg Private Limited, Harrisons Malayalam Ltd and 2 more | Director | 25 Jan 2021 | 5 Years 9 Months | Current |
| Sachin Rajkumar Nandgaonkar Also directs: Ajax Engineering Limited, Vibgyor Pixel Prints Private Limited, Sterlite Electric Limited and 1 more | Director | 23 Jan 2015 | 11 Years 9 Months | Current |
| Zahabiya Habil Khorakiwala | Director | 29 Oct 2015 | 11 Years 0 Months | Current |
Showing 6 of 13 current directors. View all directors
Peer comparison
RPG Life Sciences Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| RPG Life Sciences Limitedthis company | ₹707.52 Cr (FY 2026) | ₹109.67 Cr | 15.5% | 8.3% | 1,197 | Mumbai, Maharashtra, India |
| Wallace Pharmaceuticals Private Limited | ₹673.06 Cr (FY 2025) | 16.0% | Goa, India | |||
| Anuh Pharma Limited | ₹670.97 Cr (FY 2025) | 2.0% | Mumbai, Maharashtra, India | |||
| Venus Remedies Limited | ₹668.84 Cr (FY 2025) | 9.0% | Chandigarh, India | |||
| Tablets (India) Ltd | ₹667.39 Cr (FY 2025) | 9.0% | Chennai, Tamil Nadu, India | |||
| Ami Lifesciences Pvt Ltd | ₹659.86 Cr (FY 2025) | 20.0% | Vadodara, Gujarat, India | |||
| Lincoln Pharmaceuticals Ltd | ₹645.71 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Nosch Labs Private Limited | ₹643.87 Cr (FY 2025) | 5.0% | Hyderabad, Telangana, India | |||
| Ind Swift Laboratories Limited | ₹643.09 Cr (FY 2025) | -64.0% | Chandigarh, India |
To see the full peer comparison of RPG Life Sciences Limited, buy the company report.
Auditor
RPG Life Sciences Limited is audited by S R B C & CO LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S R B C & CO LLP | FY 2023 | 324982E/E300003 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 73.00%, foreign institutional investors hold 1.00%, domestic institutional investors hold 8.60% and retail and other public shareholders hold 17.40%.
Sep 2026
QUARTER
73.00% Promoters
8.60% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
17.40% Retail & Others
Promoter holding - history
Now 73.00% · Sep 2026High 73.00% · Dec 2025Low 73.00% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 73.00% | 73.00% | 73.00% | 73.00% |
| Public | 27.00% | 27.00% | 27.00% | 27.00% |
Charges & borrowings
Open charges
₹65.92 Cr
Satisfied charges
₹71.07 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 12 Sep 2009 | 10181270 | Others | ₹65.92 Cr | Open | |
| 12 Apr 2017 | 100093101 | Others | ₹20 Cr | Satisfied | |
| 25 Jan 2012 | 10333274 | Export Import Bank of India | ₹7.55 Cr | Satisfied | |
| 28 Jan 2011 | 10265944 | Export-Import Bank of India | ₹7 Cr | Satisfied | |
| 14 Jul 2010 | 10272760 | Export Import Bank of India | ₹3.4 Cr | Satisfied |
To see the full charge records of RPG Life Sciences Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
RPG Life Sciences Limited has 37 deals on record (32 market trades, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹5.07 Cr; the latest was in April 2026.
Total deals
37
Market trades
32
Secondary share transfers
3
Acquisition
1
Funding round
1
Disclosed funding
₹5.07 Cr
Deals on record (5 of 37)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2026 | Market trade | ₹24.8 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
| Sep 2021 | Market trade | ₹10.02 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
| Sep 2021 | Market trade | ₹5.34 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
| Sep 2021 | Market trade | ₹9.2 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: Globe Capital Market Limited , Ektara Enterprises LLP , 2 individuals Seller: Rockstar Securities Services Private Limited , Singhi Dinesh Kumar Huf, Axis Bank Limited |
To see the full deal history of RPG Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
RPG Life Sciences Limited has 205 court cases on record: 99 filed by RPG Life Sciences, 106 filed against it. 37 cases are pending and 168 are disposed.
Total cases
205
Filed by the company
99
Filed against the company
106
Pending
37
Disposed
168
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 107 | 51 | 28 |
| High courts | 97 | 55 | 9 |
| Supreme Court | 1 | 0 | 0 |
Cases on record (5 of 205)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMARY CASE) | Filed by the company against M/S DRS Consultants Private Limited and 2 others | Pending |
| District court, Hyderabad CCC, Telangana | Criminal complaint | Filed against the company by HDFC Bank Ltd. Rep by Mr.Syed Shafiuddin | Disposed |
| District court, Bharuch, Gujarat | Court case (REFER-T-LC) | Filed against the company by an individual | Pending |
| District court, Medchal Malkajgiri, Telangana | Criminal complaint | Filed against the company by Union of India, Rep. by Drugs Inspector, Naveen Reddy Kandimalla | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by PR Commissioner of Income Tax 5 Mumbai | Pending |
To see the full case history of RPG Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
RPG Life Sciences Limited was last rated by Icra on 28 Feb 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 28 Feb 2022 |
To see the full credit ratings and regulatory alerts of RPG Life Sciences Limited, buy the company report.
MSME payment delays
RPG Life Sciences Limited has 10 MSME Form 1 returns on record between 2020 and 2023, listing 173 overdue payments to 58 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 58)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| B Built Tech India Private Limited | |||
| Mahim Polyprints Private Limited | |||
| Solas Fire and Safety Enterprises Ltd | |||
| an individual supplier |
To see the full MSME payment records of RPG Life Sciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
RPG Life Sciences Limited has a workforce of 1,197 employees on its EPFO records as of Apr 01, 2024, across 2 active EPFO establishments.
Employee count
1,197
Active EPFO establishments
2
Employee growth
-1.4%
GST
RPG Life Sciences has 19 GST registrations: 17 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
19
Active
17
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AADCR8060K1Z1 | Maharashtra | Active | 01 Jul 2017 |
| 27AADCR8060K2Z0 | Maharashtra | Active | 29 Jul 2017 |
| 03AADCR8060K1ZB | Punjab | Active | 01 Jul 2017 |
| 07AADCR8060K1Z3 | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of RPG Life Sciences Limited, buy the company report.
Recent activity
RPG Life Sciences Limited has 54 board changes on record since 2007: 34 appointments and 20 cessations. The latest: Pratit Prahalad Samdani was appointed as Additional Director on 29 Apr 2026.
Appointed
Pratit Prahalad Samdani was appointed as Additional Director.
Filing
Rpg Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others of Rs. 65.92 Cr registered on 12 Sep 2009 with Charge ID 10181270 was modified on 29 Oct 2025.
AGM
Rpg Life Sciences Limited last Annual general meeting of members was held on 16 Jul 2025 as per latest MCA records.
Appointed
Ashok Nair was appointed as Managing Director.
Appointed
Yugal Kishor Chothuram Sikri was appointed as Director.
Appointed
Vasundhara Apoorva Patni was appointed as Director.
Ceased
Lalit Surajmal Kanodia ceased to be Director.
Ceased
Mahesh Shrikrishna Gupta ceased to be Director.
Ceased
Narendra Kumar Anand Ambwani ceased to be Director.
Appointed
Anilkumar Matai was appointed as Additional Director.
Appointed
Hiten Kantilal Kotak was appointed as Additional Director.
68 earlier events are in the company report.
News
RPG Life: No Significant Effect On Manufacturing Costs Of Oncology Drugs - Interview
RPG Life: Reports Gross Margin Improved By 260 Basis Points Year Over Year In Challenging Conditions - Interview
RPGLIFE: Q2 SL NET PROFIT 233M RUPEES VS 369M (YOY)
RPGLIFE: Q2 EBITDA 326M RUPEES VS 390M (YOY); Q2 EBITDA MARGIN 16.88% VS 21.48% (YOY)
RPGLIFE: Q2 EBITDA 326M RUPEES VS 390M (YOY); Q2 EBITDA MARGIN 16.88% VS 21.48% (YOY)
RPG Life Sciences: Subsidiary RPG Active Pharma Gets Approval to Merge Actis Generics to Streamline Operations, Cut Costs, and Boost Efficiency.
Frequently asked questions
RPG Life Sciences is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 29 March 2007 (19+ years old) and is registered under CIN L24232MH2007PLC169354. Listed on BSE: 532983 and NSE: RPGLIFE.
RPG Life Sciences reported revenue of ₹707.52 Cr for FY 2025-26 (up 8.3% YoY) based on consolidated financials.
RPG Life Sciences has 13 current directors:
- Ashok Nair - Managing Director
- Manojkumar Madangopal Maheshwari - Director
- Yugal Kishor Chothuram Sikri - Director
- Harsh Vardhan Goenka - Director
- Rajat Bhargava - Director
- Sachin Rajkumar Nandgaonkar - Director
- Zahabiya Habil Khorakiwala - Director
- Bhaskar Vemban Iyer - Director
- Vasundhara Apoorva Patni - Director
- Radhika Gupta - Additional Director
- Anilkumar Matai - Additional Director
- Hiten Kantilal Kotak - Additional Director
- Pratit Prahalad Samdani - Additional Director
The latest financial statements of RPG Life Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 16 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of RPG Life Sciences is 27AADCR8060K1Z1, registered in Maharashtra. The company has 19 GST registrations in all, of which 17 are active and 2 are cancelled or inactive. Other active GSTINs include 27AADCR8060K2Z0 (Maharashtra), 03AADCR8060K1ZB (Punjab), 07AADCR8060K1Z3 (Delhi).
The CIN (Corporate Identification Number) of RPG Life Sciences is L24232MH2007PLC169354. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. RPG Life Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 532983) and NSE (symbol: RPGLIFE).
RPG Life Sciences has 205 court cases on record: 99 filed by the company and 106 filed against it. 37 are pending. Most are in the district courts.
RPG Life Sciences was incorporated on 29 March 2007, making it 19+ years old. It is registered with the Registrar of Companies, Mumbai.
RPG Life Sciences has 37 deals on record (32 market trades, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹5.07 Cr; the latest was in April 2026.
The peers of RPG Life Sciences by revenue are Wallace Pharmaceuticals Private Limited, Anuh Pharma Limited, Venus Remedies Limited, Tablets (India) Ltd, Ami Lifesciences Pvt Ltd and 3 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pratit Prahalad Samdani was appointed as Additional Director on 29 Apr 2026. Ashok Nair was appointed as Managing Director on 01 May 2025. Yugal Kishor Chothuram Sikri was appointed as Director on 01 May 2025. RPG Life Sciences has 54 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages